Multiplicity in randomised trials I: endpoints and treatments. (Q53622606)

16 May 2018

title

Multiplicity in randomised trials I: endpoints and treatments. (English)

1 reference

16 May 2018

2

David A Grimes

1 reference

16 May 2018

1

Kenneth F Schulz

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 April 2005

1 reference

16 May 2018

published in

The Lancet

1 reference

16 May 2018

volume

365

1 reference

16 May 2018

issue

9470

1 reference

16 May 2018

page(s)

1591-1595

1 reference

16 May 2018

What's wrong with Bonferroni adjustments

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Multiplicity in randomised trials II: subgroup and interim analyses

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

No adjustments are needed for multiple comparisons

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Multiple comparisons and related issues in the interpretation of epidemiologic data

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Statistics in medical journals: some recent trends

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

P-value interpretation and alpha allocation in clinical trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Quantitative evaluation of multiplicity in epidemiology and public health research.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Sample size calculations in randomised trials: mandatory and mystical

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Sifting the evidence-what's wrong with significance tests?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Clinical trials with multiple outcomes: A statistical perspective on their design, analysis, and interpretation

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Statistical power, sample size, and their reporting in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

Industry, Government, and Academic Panel Discussion on Multiple Comparisons in a “Real” Phase Three Clinical Trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(05)66461-6

7 January 2021

10.1016/S0140-6736(05)66461-6

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018